Loading
A phase 1/2 trial of BPX-501 dose 1 in acute lymphoblastic leukaemia, non-Hodgkin lymphoma and myelodysplastic syndromes / neoplasms, run by Bellicum Pharmaceuticals, active and no longer recruiting.
Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant is a phase 1/2 interventional study registered as NCT01744223 by Bellicum Pharmaceuticals, with 36 participants enrolled, started 2013-03 and due to reach its primary completion in 2019-10-09. Interventions recorded: BPX-501 dose 1, Rimiducid, BPX-501 dose 2, BPX-501 dose 3, BPX-501 dose 4 and SCT.
Shares Bellicum Pharmaceuticals, Myelodysplastic syndromes / neoplasms (MDS), Acute lymphoblastic leukaemia, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute lymphoblastic leukaemia, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Acute lymphoblastic leukaemia, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute lymphoblastic leukaemia and the tag pipeline.
Shares Acute lymphoblastic leukaemia, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Acute lymphoblastic leukaemia, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute lymphoblastic leukaemia and the tag pipeline.
Shares Acute lymphoblastic leukaemia and the tag pipeline.